Table 10 Differences between CACProg− and CACProg− + in therapy.
Parameters | CAC-Prog− (n = 17) | CAC-Prog+ (n = 50) | p |
|---|---|---|---|
Gender (n) (M/F) | 7/10 | 20/30 | 0.17 |
Type of dialysis n (%) (No/HD/PD) | 1/12/4 (7/70/23) | 12/34/4 (24/68/8) | 0.95 |
Kind of transplant n (%) (deceased donor/living donor) | 14/3 (82/12) | 45/5 (90/10) | 0.40 |
Calcineurin Inhibitors therapy T5 n (%) (No/Cya/FK) | 1/3/13 (7/17/76) | 10/1/39 (20/2/78) | 0.04 |
Steroid Therapy T5 n (%) (No/Yes) | 1/16 (6/94) | 1/49 (2/98) | 0.42 |
mTor-i therapy T5 n (%) (No/Yes) | 16/1 (94/6) | 39/11 (78/22) | 0.20 |
MMF therapy T5 n (%) (No/Yes) | 0/17 (0/100) | 3/47 (6/94) | 0.39 |
Number of antihypertensive drugs (%) | |||
0 | 5 | 8 | 0.69 |
1 | 36 | 18 | |
2 | 43 | 38 | |
3 | 11 | 28 | |
>3 | 5 | 8 | |
